COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

UniProt Expands Collaboration With CPTAC

UniProt, the leading online protein reference library, has expanded its collaboration with the National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC). In addition to searching for a protein-of-interest in UniProt, which includes cross-reference links to the NCI CPTAC ...


CPTAC and FDA publish findings of a community effort to identify and correct mislabeled samples in multi-omics studies

In biomedical research, sample mislabeling or incorrect annotation has been a long-standing issue contributing to irreproducible results and invalid conclusions. These issues are particularly prevalent in large scale multi-omics studies, in which multiple different omics experiments are carried out ...


CPTAC Assists with CLSI C64: Advancing Quantitative Protein/Peptide Mass Spectrometry Tests Towards Medical Laboratories

Protein/Peptide mass spectrometry (MS) is an enabling technology that is ideally suited for precision diagnostics, due to its quantitative measurements that can be multiplexed and its ability to directly identify proteoforms. As a result, interest on the widespread implementation of quantitative ...


The Next Horizon in Precision Oncology

Where is cancer research headed in the next decade? Scientists and oncologists at the National Cancer Institute share their thoughts on the NEXT HORIZON IN PRECISION ONCOLOGY - proteogenomics.


CPTAC Helps to Identify New Roles for TGFβ in the DNA Damage Response

TGFβ is a cytokine with many, often paradoxical, roles in cancer biology. Acting as a tumor suppressor, TGFβ exerts negative control on epithelial cell proliferation - a function that tumor cells must overcome in order to progress to malignant disease. On the other hand, TGFβ also acts as a pro- ...


CPTAC Researchers Expand the use of MSFragger to Search N- and O-linked Glycopeptides

CPTAC researchers out of the University of Michigan have hit another home run. The Nesvizhskii lab, developer of the FragPipe proteomics pipeline, has developed an extension of its MSFragger flagship software to now identify N- and O-linked glycopeptides. The study was recently published in Nature ...


NCI’s International Cancer Proteogenome Consortium Welcomes Three New Member Institutions in the Global Fight Against Cancer

The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the signing of two new memoranda of understanding (MOUs) for international cancer research and care, as well as new efforts in the emerging scientific area of proteogenomics for precision oncology. MOUs ...


Aggressive Brain Tumor Mapped in Genetic, Molecular Detail

Glioblastoma is among the most aggressive and devastating of cancers. While rare compared with other cancers, it’s the most common type of brain cancer. Even with intensive therapy, relatively few patients survive longer than two years after diagnosis, and fewer than 10% of patients survive beyond ...


Dysregulation of Glycosylation in Prostate Cancer Cells Affect Extracellular Vesicle Proteome

Prostate cancer screening is typically done by evaluation of levels of prostate-specific antigens (PSA). Unfortunately, its effectiveness in stratifying low risk patients from those with aggressive (AG) prostate cancer is poor. Localized in the Golgi, α (1,6) fucosyltranferase (FUT8), a ...


Proteogenomics Offers Insight to Treating Head and Neck Squamous Cell Carcinoma

Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer. A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment.


Pages